Corient Private Wealth LLC Sells 405 Shares of Repligen Co. (NASDAQ:RGEN)

Corient Private Wealth LLC reduced its stake in shares of Repligen Co. (NASDAQ:RGEN) by 11.0% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 3,281 shares of the biotechnology company’s stock after selling 405 shares during the period. Corient Private Wealth LLC’s holdings in Repligen were worth $472,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of RGEN. CBIZ Investment Advisory Services LLC bought a new stake in Repligen in the 4th quarter valued at $58,000. Natixis Advisors LLC increased its holdings in shares of Repligen by 31.8% in the fourth quarter. Natixis Advisors LLC now owns 44,317 shares of the biotechnology company’s stock worth $6,379,000 after purchasing an additional 10,692 shares during the last quarter. Swiss National Bank lifted its position in shares of Repligen by 0.9% in the fourth quarter. Swiss National Bank now owns 104,700 shares of the biotechnology company’s stock worth $15,071,000 after buying an additional 900 shares in the last quarter. Daiwa Securities Group Inc. boosted its stake in Repligen by 29.4% during the fourth quarter. Daiwa Securities Group Inc. now owns 24,046 shares of the biotechnology company’s stock valued at $3,461,000 after buying an additional 5,466 shares during the last quarter. Finally, Amundi grew its holdings in Repligen by 11.4% during the 4th quarter. Amundi now owns 85,863 shares of the biotechnology company’s stock valued at $13,283,000 after buying an additional 8,790 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on RGEN. StockNews.com cut shares of Repligen from a “hold” rating to a “sell” rating in a research report on Friday, February 21st. HC Wainwright restated a “buy” rating and set a $180.00 target price on shares of Repligen in a research report on Friday, February 21st. Royal Bank of Canada lifted their price target on Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a research report on Friday, February 21st. JPMorgan Chase & Co. upped their price objective on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Finally, Canaccord Genuity Group lifted their target price on Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a report on Friday, February 21st. One analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $178.64.

Repligen Trading Down 2.7 %

RGEN stock opened at $133.41 on Friday. The company has a market capitalization of $7.49 billion, a PE ratio of -261.59, a P/E/G ratio of 4.54 and a beta of 0.95. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. Repligen Co. has a 12 month low of $113.50 and a 12 month high of $184.98. The firm’s 50-day moving average is $154.21 and its 200 day moving average is $148.15.

Repligen (NASDAQ:RGEN) last issued its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The business had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. On average, research analysts anticipate that Repligen Co. will post 1.72 EPS for the current year.

Insiders Place Their Bets

In related news, Director Margaret Pax bought 250 shares of the company’s stock in a transaction on Monday, March 17th. The shares were acquired at an average price of $150.69 per share, with a total value of $37,672.50. Following the transaction, the director now owns 1,043 shares of the company’s stock, valued at $157,169.67. The trade was a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 1.20% of the company’s stock.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.